Paradigm Shift

In Cancer Treatment

Learn More

Salarius is a cancer-focused biotechnology company developing treatments for patients who need them the most.

Our technology targets the epigenetic causes of cancer which is the study of the regulatory system that controls how genes are turned “on” or “off.” In certain cancers, the proteins that regulate gene expression become dysregulated and incorrectly turn genes “on” or “off,” which in some cases leads to cancer progression. Drugs that are able to safely modify the activity of these epigenetic regulators may correct the gene changes that are driving disease. Our technology may also apply to hormonal cancers such as prostate, breast, ovarian cancer and perhaps other conditions like leukemia.

Salarius is the recipient of a 3-year $18.7 million Cancer Prevention and Research Institute of Texas (CPRIT) New Company Product Development award, is housed in the Jlabs@TMC facility in Houston, Texas and receives support from organizations like the National Pediatric Cancer Foundation.

News & Events

June 19, 2020


The 2020 Annual Meeting of Stockholders

Due to the emerging public health impact of the coronavirus outbreak and to support the health and well-being of our stockholders and employees, the Annual Meeting will be held in a virtual meeting format only. Shareholders may access the live webcast by visiting . Login for the call begins at 9:45 a.m. CT.


June 17, 2020


Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee

Live Teleconference Information

Format: A 20-minute presentation by Salarius; a 10-minute Q&A session for the subcommittee; 1 hour for discussion

Webcast Information:  The meeting webcast can be accessed at the following web address:
Note: At the access page, please sign in as a guest. No password is required.

The webcast will be broadcast using Adobe Connect. You can check to determine if your computer has the correct plug-ins in order to view the webcast by accessing the following web site:

Webinar Link